Press release
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
This marks the third consecutive year that Castle has been recognized with a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nThis marks the third consecutive year that Castle has been recognized with a MedTech Breakthrough Award for its innovative testing solutions\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh annual MedTech Breakthrough Awards program for its innovative TissueCypher® Barrett’s Esophagus test. TissueCypher is Castle’s risk-stratification test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus (BE).\n\n\nBE is a serious complication of gastroesophageal reflux disease (GERD) and a risk factor for the development of esophageal cancer, one of the fastest-growing cancers (by incidence) in the U.S., with a five-year survival rate of less than 20%.1\n\n\n“Patients with higher grades of BE generally receive effective interventions, such as ablation therapy, to halt the progression of BE to esophageal cancer,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “However, the majority of BE patients are graded with lower grades of BE, or as non-dysplastic. On a population basis, these lower-graded patients are predicted to have a low likelihood of developing cancer, but these lower graded patients make up the majority of patients who end up progressing to esophageal cancer. This disconnect shows there is a significant clinical need for personalized, biologically based risk-stratification information to enable improved alignment between risk of progression and use of effective interventions.\n\n\n\"The personalized risk-stratification information provided by TissueCypher was discovered, developed and validated to fill this clinical need, and the harnessing of artificial intelligence was part of the solution. We are incredibly honored to once again be recognized with a MedTech Breakthrough Award for our innovation in testing solutions that guide patient care.”\n\n\nThe TissueCypher test provides clinicians with important information about a patient’s individual risk of progression to esophageal cancer based on advanced analysis of biopsied tissue to guide more informed and risk-aligned management of BE patients.\n\n\n“Mos...